Global Cancer Antibody Drug Conjugates Market: 2020 - 2030 Global Cancer Antibody Drug Conjugates Market Opportunity > US$ 50 ...

Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech ...

Ludwig Cancer Research scientists have devised new types of chimeric antigen-receptor (CAR) T cells—a type of cancer ...

Older adults with metastatic cancer living in Mexico experience a high time toxicity burden, spending about 21% of their days ...

Tanya Gupta, MD, discusses the use of ado-trastuzumab emtansine for the treatment of patients with HER2-positive breast cancer.

Changes in the gene activity of immune cells may help flag people who have multiple sclerosis or are likely to develop it, a ...

Under the revised agreement, both companies will co-develop four Radio-DARPin programs; each company will have the right to commercialize two ...

Scientists have engineered CAR-T cells with on/off switches activated by existing drugs, enhancing safety in cancer therapy.

DelveInsight's Antibody-drug Conjugate Market Insights report provides the current and forecast market analysis, individual ...

DelveInsight's 'Antibody-drug Conjugates in Oncology Competitive Landscape – 2024' report provides comprehensive global ...

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") is pleased to announce the issuance of U.S. Patent No.

Tevogen is driven by a team of experienced industry leaders and scientists with drug development and global product launch experience. Tevogen’s leadership believes that accessible personalized ...